Carcinoembryonic Antigen (CEA) market- Forecast to 2027

Browse full report@

About Carcinoembryonic Antigen (CEA):

CEA stands for Carcinoembryonic antigen. CEA is a form of glycoprotein molecule that is generated by cells of the gastrointestinal tract during embryonic development. It is produced in very small quantity after birth. The level of CEA in the bloodstream is thus relatively low unless certain diseases - including certain forms of cancer - are present. Carcinoembryonic antigen (CEA) portrays an arrangement of highly related glycoproteins involved in cell attachment. CEA is normally present just at low levels in the blood of healthy adults. In any case, If the serum levels are brought up in some type of cancer, which implies that it can be used as a tumor maker in clinical tests. Serum levels can likewise be raised in overwhelming smokers. CEA are glycosyl phosphatidyl inositol (GPI) cell surface anchored glycoproteins whose specific  sialofucosylated  glycoforms serve as functional colon carcinoma L-selectin and E-selectin ligands, which may be important to the metastatic dissemination of colon carcinoma cells. Immunologically they are portrayed as individuals from the CD66 cluster of differentiation

A normal level of CEA is equal to or less than 3 nanograms per milliliter (ng/mL). Most healthy adults have levels below this amount. CEA levels will generally return to normal between one and four months after cancer has been successfully removed from a patients system.

Request for toc of this report@

Major Market Players:

Roche Diagnostics, Quest Diagnostics, Correlogic Systems, Inc., GenWay Biotech Inc.

Market growth driver:

With the diagnosis of different types of cancers in the globe, Carcinoembryonic Antigen (CEA) test helps the doctor to diagnose and find out the type of cancer present in the patient’s body. With this unique quality CEA tests demand and market will be in huge demand and this market will be highly lucrative.

Check discount of this report @

Regional Analysis:

North America

Carcinoembryonic Antigen (CEA) market for North America is one of the biggest markets in the globe the main reason behind this is the Cancer rate in the North American countries. Cancer usually develops in older people 86% of all cancers in the United States are diagnosed in people 50 years of age or older.

Typical behaviors also increase the risk of being diagnosed by cancer, these include eating unhealthy diet, heavy smocking or not being physically active. According to cancer facts and figures 2016 US, in a life time the probable risk of developing cancer     in men in 42%, one in two men and for women it is 38% that is one in three women. It is estimated that 16,85,210 new cancer case are found in the US every year out of which 5,95,690 have ended up in deaths. With the rate of growth cancer is facing it can easily be estimated that the amount of test taken to diagnose cancer will increase, out of which one test is Carcinoembryonic Antigen (CEA) test. Hence this market will gain huge demand and is expect to grow at a very high growth rate.